Acute myeloid leukemia (AML) remains the most common form of acute leukemia among adults and accounts for the largest number of annual deaths due to leukemias in the United States. The NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines) for AML provide recommendations on the diagnostic evaluation and workup for AML, risk assessment based on cytogenetic and molecular features, treatment options for induction and consolidation therapies for younger and older (age ≥ 65 years) adult patients, and key supportive care considerations.

  • 1

    SiegelRNaishadhamDJemalA. Cancer statistics, 2012. CA Cancer J Clin2012;62:1029.

  • 2

    National Cancer Institute. SEER Stat Fact Sheets: Acute Myeloid Leukemia. Available at: http://seer.cancer.gov/statfacts/html/amyl.html. Accessed August 1 2011.

    • Search Google Scholar
    • Export Citation
  • 3

    SmithMBarnettMBassanR. Adult acute myeloid leukaemia. Crit Rev Oncol Hematol2004;50:197222.

  • 4

    LeoneGPaganoLBen-YehudaDVosoMT. Therapy-related leukemia and myelodysplasia: susceptibility and incidence. Haematologica2007;92:13891398.

    • Search Google Scholar
    • Export Citation
  • 5

    PaganaLPulsoniATostiME. Clinical and biological features of acute myeloid leukaemia occurring as second malignancy: GIMEMA archive of adult acute leukaemia. Br J Haematol2001;112:109117.

    • Search Google Scholar
    • Export Citation
  • 6

    PulsoniAPaganoLLo CocoF. Clinicobiological features and outcome of acute promyelocytic leukemia occurring as a second tumor: the GIMEMA experience. Blood2002;100:19721976.

    • Search Google Scholar
    • Export Citation
  • 7

    KayserSDohnerKKrauterJ. The impact of therapy-related acute myeloid leukemia (AML) on outcome in 2853 adult patients with newly diagnosed AML. Blood2011;117:21372145.

    • Search Google Scholar
    • Export Citation
  • 8

    LarsonRA. Etiology and management of therapy-related myeloid leukemia. Hematology Am Soc Hematol Educ Program2007:453459.

  • 9

    MauritzsonNAlbinMRylanderL. Pooled analysis of clinical and cytogenetic features in treatment-related and de novo adult acute myeloid leukemia and myelodysplastic syndromes based on a consecutive series of 761 patients analyzed 1976–1993 and on 5098 unselected cases reported in the literature 1974–2001. Leukemia2002;16:23662378.

    • Search Google Scholar
    • Export Citation
  • 10

    CarneyDAWestermanDATamCS. Therapy-related myelodysplastic syndrome and acute myeloid leukemia following fludarabine combination chemotherapy. Leukemia2010;24:20562062.

    • Search Google Scholar
    • Export Citation
  • 11

    CzaderMOraziA. Therapy-related myeloid neoplasms. Am J Clin Pathol2009;132:410425.

  • 12

    HosingCMunsellMYazjiS. Risk of therapy-related myelodysplastic syndrome/acute leukemia following high-dose therapy and autologous bone marrow transplantation for non-Hodgkin's lymphoma. Ann Oncol2002;13:450459.

    • Search Google Scholar
    • Export Citation
  • 13

    LenzGDreylingMSchiegnitzE. Moderate increase of secondary hematologic malignancies after myeloablative radiochemotherapy and autologous stem-cell transplantation in patients with indolent lymphoma: results of a prospective randomized trial of the German Low Grade Lymphoma Study Group. J Clin Oncol2004;22:49264933.

    • Search Google Scholar
    • Export Citation
  • 14

    BorthakurGLinEJainN. Survival is poorer in patients with secondary core-binding factor acute myelogenous leukemia compared with de novo core-binding factor leukemia. Cancer2009;115:32173221.

    • Search Google Scholar
    • Export Citation
  • 15

    BeaumontMSanzMCarliPM. Therapy-related acute promyelocytic leukemia. J Clin Oncol2003;21:21232137.

  • 16

    HarrisNLJaffeESDieboldJ. World Health Organization classification of neoplastic diseases of the hematopoietic and lymphoid tissues: report of the Clinical Advisory Committee meeting—Airlie House, Virginia, November 1997. J Clin Oncol1999;17:38353849.

    • Search Google Scholar
    • Export Citation
  • 17

    ChesonBDBennettJMKopeckyKJ. Revised recommendations of the International Working Group for Diagnosis, Standardization of Response Criteria, Treatment Outcomes, and Reporting Standards for Therapeutic Trials in acute myeloid leukemia. J Clin Oncol2003;21:46424649.

    • Search Google Scholar
    • Export Citation
  • 18

    SwerdlowSHCampoEHarrisNL eds. WHO classification of tumours of haematopoietic and lymphoid tissues4th ed.Lyon: IARC; 2008.

  • 19

    ByrdJCMrozekKDodgeRK. Pretreatment cytogenetic abnormalities are predictive of induction success, cumulative incidence of relapse, and overall survival in adult patients with de novo acute myeloid leukemia: results from Cancer and Leukemia Group B (CALGB 8461). Blood2002;100:43254336.

    • Search Google Scholar
    • Export Citation
  • 20

    GrimwadeDWalkerHOliverF. The importance of diagnostic cytogenetics on outcome in AML: analysis of 1,612 patients entered into the MRC AML 10 trial. The Medical Research Council Adult and Children's Leukaemia Working Parties. Blood1998;92:23222333.

    • Search Google Scholar
    • Export Citation
  • 21

    SlovakMLKopeckyKJCassilethPA. Karyotypic analysis predicts outcome of preremission and postremission therapy in adult acute myeloid leukemia: a Southwest Oncology Group/Eastern Cooperative Oncology Group Study. Blood2000;96:40754083.

    • Search Google Scholar
    • Export Citation
  • 22

    BreemsDAVan PuttenWLDe GreefGE. Monosomal karyotype in acute myeloid leukemia: a better indicator of poor prognosis than a complex karyotype. J Clin Oncol2008;26:47914797.

    • Search Google Scholar
    • Export Citation
  • 23

    MedeirosBCOthusMFangM. Prognostic impact of monosomal karyotype in young adult and elderly acute myeloid leukemia: the Southwest Oncology Group (SWOG) experience. Blood2010;116:22242228.

    • Search Google Scholar
    • Export Citation
  • 24

    PerrotALuquetIPigneuxA. Dismal prognostic value of monosomal karyotype in elderly patients with acute myeloid leukemia: a GOELAMS study of 186 patients with unfavorable cytogenetic abnormalities. Blood2011;118:679685.

    • Search Google Scholar
    • Export Citation
  • 25

    BienzMLudwigMLeibundgutEO. Risk assessment in patients with acute myeloid leukemia and a normal karyotype. Clin Cancer Res2005;11:14161424.

    • Search Google Scholar
    • Export Citation
  • 26

    CairoliRBeghiniAGrilloG. Prognostic impact of c-KIT mutations in core binding factor leukemias: an Italian retrospective study. Blood2006;107:34633468.

    • Search Google Scholar
    • Export Citation
  • 27

    DohnerKSchlenkRFHabdankM. Mutant nucleophosmin (NPM1) predicts favorable prognosis in younger adults with acute myeloid leukemia and normal cytogenetics: interaction with other gene mutations. Blood2005;106:37403746.

    • Search Google Scholar
    • Export Citation
  • 28

    FaliniBNicolettiIMartelliMFMecucciC. Acute myeloid leukemia carrying cytoplasmic/mutated nucleophosmin (NPMc+ AML): biologic and clinical features. Blood2007;109:874885.

    • Search Google Scholar
    • Export Citation
  • 29

    FrohlingSSchlenkRFBreitruckJ. Prognostic significance of activating FLT3 mutations in younger adults (16 to 60 years) with acute myeloid leukemia and normal cytogenetics: a study of the AML Study Group Ulm. Blood2002;100:43724380.

    • Search Google Scholar
    • Export Citation
  • 30

    FrohlingSSchlenkRFStolzeI. CEBPA mutations in younger adults with acute myeloid leukemia and normal cytogenetics: prognostic relevance and analysis of cooperating mutations. J Clin Oncol2004;22:624633.

    • Search Google Scholar
    • Export Citation
  • 31

    PabstTMuellerBUZhangP. Dominant-negative mutations of CEBPA, encoding CCAAT/enhancer binding protein-alpha (C/EBPalpha), in acute myeloid leukemia. Nat Genet2001;27:263270.

    • Search Google Scholar
    • Export Citation
  • 32

    PaschkaPMarcucciGRuppertAS. Adverse prognostic significance of KIT mutations in adult acute myeloid leukemia with inv(16) and t(8;21): a Cancer and Leukemia Group B study. J Clin Oncol2006;24:39043911.

    • Search Google Scholar
    • Export Citation
  • 33

    SchnittgerSSchochCKernW. Nucleophosmin gene mutations are predictors of favorable prognosis in acute myelogenous leukemia with a normal karyotype. Blood2005;106:37333739.

    • Search Google Scholar
    • Export Citation
  • 34

    SchnittgerSKohlTMHaferlachT. KIT-D816 mutations in AML1-ETO-positive AML are associated with impaired event-free and overall survival. Blood2006;107:17911799.

    • Search Google Scholar
    • Export Citation
  • 35

    ThiedeCKochSCreutzigE. Prevalence and prognostic impact of NPM1 mutations in 1485 adult patients with acute myeloid leukemia (AML). Blood2006;107:40114020.

    • Search Google Scholar
    • Export Citation
  • 36

    VerhaakRGGoudswaardCSvan PuttenW. Mutations in nucleophosmin (NPM1) in acute myeloid leukemia (AML): association with other gene abnormalities and previously established gene expression signatures and their favorable prognostic significance. Blood2005;106:37473754.

    • Search Google Scholar
    • Export Citation
  • 37

    PatelJPGonenMFigueroaME. Prognostic relevance of integrated genetic profiling in acute myeloid leukemia. N Engl J Med2012;366:10791089.

    • Search Google Scholar
    • Export Citation
  • 38

    SchlenkRFDohnerKKrauterJ. Mutations and treatment outcome in cytogenetically normal acute myeloid leukemia. N Engl J Med2008;358:19091918.

    • Search Google Scholar
    • Export Citation
  • 39

    FaliniBMecucciCTiacciE. Cytoplasmic nucleophosmin in acute myelogenous leukemia with a normal karyotype. N Engl J Med2005;352:254266.

    • Search Google Scholar
    • Export Citation
  • 40

    Abu-DuhierFMGoodeveACWilsonGA. Identification of novel FLT-3 Asp835 mutations in adult acute myeloid leukaemia. Br J Haematol2001;113:983988.

    • Search Google Scholar
    • Export Citation
  • 41

    KiyoiHNaoeTNakanoY. Prognostic implication of FLT3 and N-RAS gene mutations in acute myeloid leukemia. Blood1999;93:30743080.

  • 42

    KottaridisPDGaleREFrewME. The presence of a FLT3 internal tandem duplication in patients with acute myeloid leukemia (AML) adds important prognostic information to cytogenetic risk group and response to the first cycle of chemotherapy: analysis of 854 patients from the United Kingdom Medical Research Council AML 10 and 12 trials. Blood2001;98:17521759.

    • Search Google Scholar
    • Export Citation
  • 43

    NakaoMYokotaSIwaiT. Internal tandem duplication of the flt3 gene found in acute myeloid leukemia. Leukemia1996;10:19111918.

  • 44

    WhitmanSPArcherKJFengL. Absence of the wild-type allele predicts poor prognosis in adult de novo acute myeloid leukemia with normal cytogenetics and the internal tandem duplication of FLT3: a cancer and leukemia group B study. Cancer Res2001;61:72337239.

    • Search Google Scholar
    • Export Citation
  • 45

    YamamotoYKiyoiHNakanoY. Activating mutation of D835 within the activation loop of FLT3 in human hematologic malignancies. Blood2001;97:24342439.

    • Search Google Scholar
    • Export Citation
  • 46

    KainzBHeintelDMarculescuR. Variable prognostic value of FLT3 internal tandem duplications in patients with de novo AML and a normal karyotype, t(15;17), t(8;21) or inv(16). Hematol J2002;3:283289.

    • Search Google Scholar
    • Export Citation
  • 47

    WhitmanSPMaharryKRadmacherMD. FLT3 internal tandem duplication associates with adverse outcome and gene- and microRNA-expression signatures in patients 60 years of age or older with primary cytogenetically normal acute myeloid leukemia: a Cancer and Leukemia Group B study. Blood2010;116:36223626.

    • Search Google Scholar
    • Export Citation
  • 48

    WhitmanSPRuppertASRadmacherMD. FLT3 D835/I836 mutations are associated with poor disease-free survival and a distinct gene-expression signature among younger adults with de novo cytogenetically normal acute myeloid leukemia lacking FLT3 internal tandem duplications. Blood2008;111:15521559.

    • Search Google Scholar
    • Export Citation
  • 49

    SantosFPJonesDQiaoW. Prognostic value of FLT3 mutations among different cytogenetic subgroups in acute myeloid leukemia. Cancer2011;117:21452155.

    • Search Google Scholar
    • Export Citation
  • 50

    BacherUHaferlachCKernW. Prognostic relevance of FLT3-TKD mutations in AML: the combination matters—an analysis of 3082 patients. Blood2008;111:25272537.

    • Search Google Scholar
    • Export Citation
  • 51

    MeadAJLinchDCHillsRK. FLT3 tyrosine kinase domain mutations are biologically distinct from and have a significantly more favorable prognosis than FLT3 internal tandem duplications in patients with acute myeloid leukemia. Blood2007;110:12621270.

    • Search Google Scholar
    • Export Citation
  • 52

    Barjesteh van Waalwijk van Doorn-KhosrovaniSErpelinckCMeijerJ. Biallelic mutations in the CEBPA gene and low CEBPA expression levels as prognostic markers in intermediate-risk AML. Hematol J2003;4:3140.

    • Search Google Scholar
    • Export Citation
  • 53

    GreenCLKooKKHillsRK. Prognostic significance of CEBPA mutations in a large cohort of younger adult patients with acute myeloid leukemia: impact of double CEBPA mutations and the interaction with FLT3 and NPM1 mutations. J Clin Oncol2010;28:27392747.

    • Search Google Scholar
    • Export Citation
  • 54

    PreudhommeCSagotCBoisselN. Favorable prognostic significance of CEBPA mutations in patients with de novo acute myeloid leukemia: a study from the Acute Leukemia French Association (ALFA). Blood2002;100:27172723.

    • Search Google Scholar
    • Export Citation
  • 55

    AbbasSLugthartSKavelaarsFG. Acquired mutations in the genes encoding IDH1 and IDH2 both are recurrent aberrations in acute myeloid leukemia: prevalence and prognostic value. Blood2010;116:21222126.

    • Search Google Scholar
    • Export Citation
  • 56

    ChotiratSThongnoppakhunWPromsuwichaO. Molecular alterations of isocitrate dehydrogenase 1 and 2 (IDH1 and IDH2) metabolic genes and additional genetic mutations in newly diagnosed acute myeloid leukemia patients. J Hematol Oncol2012;5:5.

    • Search Google Scholar
    • Export Citation
  • 57

    ChouWCHouHAChenCY. Distinct clinical and biologic characteristics in adult acute myeloid leukemia bearing the isocitrate dehydrogenase 1 mutation. Blood2010;115:27492754.

    • Search Google Scholar
    • Export Citation
  • 58

    MarcucciGMaharryKWuYZ. IDH1 and IDH2 gene mutations identify novel molecular subsets within de novo cytogenetically normal acute myeloid leukemia: a Cancer and Leukemia Group B study. J Clin Oncol2010;28:23482355.

    • Search Google Scholar
    • Export Citation
  • 59

    MardisERDingLDoolingDJ. Recurring mutations found by sequencing an acute myeloid leukemia genome. N Engl J Med2009;361:10581066.

  • 60

    PaschkaPSchlenkRFGaidzikVI. IDH1 and IDH2 mutations are frequent genetic alterations in acute myeloid leukemia and confer adverse prognosis in cytogenetically normal acute myeloid leukemia with NPM1 mutation without FLT3 internal tandem duplication. J Clin Oncol2010;28:36363643.

    • Search Google Scholar
    • Export Citation
  • 61

    ChouWCLeiWCKoBS. The prognostic impact and stability of Isocitrate dehydrogenase 2 mutation in adult patients with acute myeloid leukemia. Leukemia2011;25:246253.

    • Search Google Scholar
    • Export Citation
  • 62

    LeyTJDingLWalterMJ. DNMT3A mutations in acute myeloid leukemia. N Engl J Med2010;363:24242433.

  • 63

    TholFDammFLudekingA. Incidence and prognostic influence of DNMT3A mutations in acute myeloid leukemia. J Clin Oncol2011;29:28892896.

    • Search Google Scholar
    • Export Citation
  • 64

    MarcucciGMetzelerKHSchwindS. Age-related prognostic impact of different types of DNMT3A mutations in adults with primary cytogenetically normal acute myeloid leukemia. J Clin Oncol2012;30:742750.

    • Search Google Scholar
    • Export Citation
  • 65

    MarkovaJMichkovaPBurckovaK. Prognostic impact of DNMT3A mutations in patients with intermediate cytogenetic risk profile acute myeloid leukemia. Eur J Haematol2012;88:128135.

    • Search Google Scholar
    • Export Citation
  • 66

    RennevilleABoisselNNibourelO. Prognostic significance of DNA methyltransferase 3A mutations in cytogenetically normal acute myeloid leukemia: a study by the Acute Leukemia French Association. Leukemia2012;26:12471254.

    • Search Google Scholar
    • Export Citation
  • 67

    DohnerHEsteyEHAmadoriS. Diagnosis and management of acute myeloid leukemia in adults: recommendations from an international expert panel, on behalf of the European LeukemiaNet. Blood2010;115:453474.

    • Search Google Scholar
    • Export Citation
  • 68

    RolligCBornhauserMThiedeC. Long-term prognosis of acute myeloid leukemia according to the new genetic risk classification of the European LeukemiaNet recommendations: evaluation of the proposed reporting system. J Clin Oncol2011;29:27582765.

    • Search Google Scholar
    • Export Citation
  • 69

    BoisselNLeroyHBrethonB. Incidence and prognostic impact of c-Kit, FLT3, and Ras gene mutations in core binding factor acute myeloid leukemia (CBF-AML). Leukemia2006;20:965970.

    • Search Google Scholar
    • Export Citation
  • 70

    AppelbaumFRGundackerHHeadDR. Age and acute myeloid leukemia. Blood2006;107:34813485.

  • 71

    FernandezHFSunZYaoX. Anthracycline dose intensification in acute myeloid leukemia. N Engl J Med2009;361:12491259.

  • 72

    PautasCMerabetFThomasX. Randomized study of intensified anthracycline doses for induction and recombinant interleukin-2 for maintenance in patients with acute myeloid leukemia age 50 to 70 years: results of the ALFA-9801 study. J Clin Oncol2010;28:808814.

    • Search Google Scholar
    • Export Citation
  • 73

    BorthakurGKantarjianHWangX. Treatment of core-binding-factor in acute myelogenous leukemia with fludarabine, cytarabine, and granulocyte colony-stimulating factor results in improved event-free survival. Cancer2008;113:31813185.

    • Search Google Scholar
    • Export Citation
  • 74

    KantarjianHO'BrienSCortesJ. Results of intensive chemotherapy in 998 patients age 65 years or older with acute myeloid leukemia or high-risk myelodysplastic syndrome: predictive prognostic models for outcome. Cancer2006;106:10901098.

    • Search Google Scholar
    • Export Citation
  • 75

    BishopJFMatthewsJPYoungGA. A randomized study of high-dose cytarabine in induction in acute myeloid leukemia. Blood1996;87:17101717.

    • Search Google Scholar
    • Export Citation
  • 76

    BishopJFMatthewsJPYoungGA. Intensified induction chemotherapy with high dose cytarabine and etoposide for acute myeloid leukemia: a review and updated results of the Australian Leukemia Study Group. Leuk Lymphoma1998;28:315327.

    • Search Google Scholar
    • Export Citation
  • 77

    WeickJKKopeckyKJAppelbaumFR. A randomized investigation of high-dose versus standard-dose cytosine arabinoside with daunorubicin in patients with previously untreated acute myeloid leukemia: a Southwest Oncology Group study. Blood1996;88:28412851.

    • Search Google Scholar
    • Export Citation
  • 78

    MayerRJDavisRBSchifferCA. Intensive postremission chemotherapy in adults with acute myeloid leukemia. Cancer and Leukemia Group B. N Engl J Med1994;331:896903.

    • Search Google Scholar
    • Export Citation
  • 79

    KernWEsteyEH. High-dose cytosine arabinoside in the treatment of acute myeloid leukemia: Review of three randomized trials. Cancer2006;107:116124.

    • Search Google Scholar
    • Export Citation
  • 80

    BloomfieldCDLawrenceDByrdJC. Frequency of prolonged remission duration after high-dose cytarabine intensification in acute myeloid leukemia varies by cytogenetic subtype. Cancer Res1998;58:41734179.

    • Search Google Scholar
    • Export Citation
  • 81

    Al-AliHKBrandRvan BiezenA. A retrospective comparison of autologous and unrelated donor hematopoietic cell transplantation in myelodysplastic syndrome and secondary acute myeloid leukemia: a report on behalf of the Chronic Leukemia Working Party of the European Group for Blood and Marrow Transplantation (EBMT). Leukemia2007;21:19451951.

    • Search Google Scholar
    • Export Citation
  • 82

    LowenbergBPabstTVellengaE. Cytarabine dose for acute myeloid leukemia. N Engl J Med2011;364:10271036.

  • 83

    SuciuSMandelliFde WitteT. Allogeneic compared with autologous stem cell transplantation in the treatment of patients younger than 46 years with acute myeloid leukemia (AML) in first complete remission (CR1): an intention-to-treat analysis of the EORTC/GIMEMAAML-10 trial. Blood2003;102:12321240.

    • Search Google Scholar
    • Export Citation
  • 84

    BurnettAKWheatleyKGoldstoneAH. The value of allogeneic bone marrow transplant in patients with acute myeloid leukaemia at differing risk of relapse: results of the UK MRC AML 10 trial. Br J Haematol2002;118:385400.

    • Search Google Scholar
    • Export Citation
  • 85

    FaragSSRuppertASMrozekK. Outcome of induction and postremission therapy in younger adults with acute myeloid leukemia with normal karyotype: a cancer and leukemia group B study. J Clin Oncol2005;23:482493.

    • Search Google Scholar
    • Export Citation
  • 86

    KrugURolligCKoschmiederA. Complete remission and early death after intensive chemotherapy in patients aged 60 years or older with acute myeloid leukaemia: a web-based application for prediction of outcomes. Lancet2010;376:20002008.

    • Search Google Scholar
    • Export Citation
  • 87

    LowenbergBOssenkoppeleGJvan PuttenW. High-dose daunorubicin in older patients with acute myeloid leukemia. N Engl J Med2009;361:12351248.

    • Search Google Scholar
    • Export Citation
  • 88

    PautasCThomasXMerabetF. Randomized comparison of standard induction with daunorubicin (DNR) for 3 days vs idarubicin (IDA) for 3 or 4 days in AML pts aged 50 to 70 and of maintenance with interleukin 2. Final analysis of the ALFA 9801 study [abstract]. Blood2007;110(Suppl):Abstract 162.

    • Search Google Scholar
    • Export Citation
  • 89

    KantarjianHMErbaHPClaxtonD. Phase II study of clofarabine monotherapy in previously untreated older adults with acute myeloid leukemia and unfavorable prognostic factors. J Clin Oncol2010;28:549555.

    • Search Google Scholar
    • Export Citation
  • 90

    FenauxPMuftiGJHellstrom-LindbergE. Efficacy of azacitidine compared with that of conventional care regimens in the treatment of higher-risk myelodysplastic syndromes: a randomised, open-label, phase III study. Lancet Oncol2009;10:223232.

    • Search Google Scholar
    • Export Citation
  • 91

    FenauxPMuftiGJHellstrom-LindbergE. Azacitidine prolongs overall survival compared with conventional care regimens in elderly patients with low bone marrow blast count acute myeloid leukemia. J Clin Oncol2010;28:562569.

    • Search Google Scholar
    • Export Citation
  • 92

    CashenAFSchillerGJO'DonnellMRDiPersioJF. Multicenter, phase II study of decitabine for the first-line treatment of older patients with acute myeloid leukemia. J Clin Oncol2010;28:556561.

    • Search Google Scholar
    • Export Citation
  • 93

    ThomasXGDmoszynskaAWierzbowskaA. Results from a randomized phase III trial of decitabine versus supportive care or low-dose cytarabine for the treatment of older patients with newly diagnosed AML [abstract]. J Clin Oncol2011;29(Suppl1):Abstract 6504.

    • Search Google Scholar
    • Export Citation
  • 94

    BurnettAKMilliganDPrenticeAG. A comparison of low-dose cytarabine and hydroxyurea with or without all-trans retinoic acid for acute myeloid leukemia and high-risk myelodysplastic syndrome in patients not considered fit for intensive treatment. Cancer2007;109:11141124.

    • Search Google Scholar
    • Export Citation
  • 95

    GardinCTurlurePFagotT. Postremission treatment of elderly patients with acute myeloid leukemia in first complete remission after intensive induction chemotherapy: results of the multicenter randomized Acute Leukemia French Association (ALFA) 9803 trial. Blood2007;109:51295135.

    • Search Google Scholar
    • Export Citation
  • 96

    HerrALLabopinMBlaiseD. HLA-identical sibling allogeneic peripheral blood stem cell transplantation with reduced intensity conditioning compared to autologous peripheral blood stem cell transplantation for elderly patients with de novo acute myeloid leukemia. Leukemia2007;21:129135.

    • Search Google Scholar
    • Export Citation
  • 97

    StorbR. Can reduced-intensity allogeneic transplantation cure older adults with AML?Best Pract Res Clin Haematol2007;20:8590.

  • 98

    EsteyEde LimaMTibesR. Prospective feasibility analysis of reduced-intensity conditioning (RIC) regimens for hematopoietic stem cell transplantation (HSCT) in elderly patients with acute myeloid leukemia (AML) and high-risk myelodysplastic syndrome (MDS). Blood2007;109:13951400.

    • Search Google Scholar
    • Export Citation
  • 99

    MartinoRValcarcelDBrunetS. Comparable non-relapse mortality and survival after HLA-identical sibling blood stem cell transplantation with reduced or conventional-intensity preparative regimens for high-risk myelodysplasia or acute myeloid leukemia in first remission. Bone Marrow Transplant2008;41:3338.

    • Search Google Scholar
    • Export Citation
  • 100

    KurosawaSYamaguchiTUchidaN. Comparison of allogeneic hematopoietic cell transplantation and chemotherapy in elderly patients with non-M3 acute myelogenous leukemia in first complete remission. Biol Blood Marrow Transplant2011;17:401411.

    • Search Google Scholar
    • Export Citation
  • 101

    FaragSSMaharryKZhangMJ. Comparison of reduced-intensity hematopoietic cell transplantation with chemotherapy in patients age 60–70 years with acute myelogenous leukemia in first remission. Biol Blood Marrow Transplant2011;17:17961803.

    • Search Google Scholar
    • Export Citation
  • 102

    MartinMGAugustinKMUyGL. Salvage therapy for acute myeloid leukemia with fludarabine, cytarabine, and idarubicin with or without gemtuzumab ozogamicin and with concurrent or sequential G-CSF. Am J Hematol2009;84:733737.

    • Search Google Scholar
    • Export Citation
  • 103

    WierzbowskaARobakTPlutaA. Cladribine combined with high doses of arabinoside cytosine, mitoxantrone, and G-CSF (CLAG-M) is a highly effective salvage regimen in patients with refractory and relapsed acute myeloid leukemia of the poor risk: a final report of the Polish Adult Leukemia Group. Eur J Haematol2008;80:115126.

    • Search Google Scholar
    • Export Citation
  • 104

    MontilloMMirtoSPettiMC. Fludarabine, cytarabine, and G-CSF (FLAG) for the treatment of poor risk acute myeloid leukemia. Am J Hematol1998;58:105109.

    • Search Google Scholar
    • Export Citation
  • 105

    ParkerJEPagliucaAMijovicA. Fludarabine, cytarabine, G-CSF and idarubicin (FLAG-IDA) for the treatment of poor-risk myelodysplastic syndromes and acute myeloid leukaemia. Br J Haematol1997;99:939944.

    • Search Google Scholar
    • Export Citation
  • 106

    AmadoriSArceseWIsacchiG. Mitoxantrone, etoposide, and intermediate-dose cytarabine: an effective and tolerable regimen for the treatment of refractory acute myeloid leukemia. J Clin Oncol1991;9:12101214.

    • Search Google Scholar
    • Export Citation
  • 107

    BeckerPSKantarjianHMAppelbaumFR. Clofarabine with high dose cytarabine and granulocyte colony-stimulating factor (G-CSF) priming for relapsed and refractory acute myeloid leukaemia. Br J Haematol2011;155:182189.

    • Search Google Scholar
    • Export Citation
  • 108

    JensenMKJohansenPStentoftJ. Salvage therapy with low-dose cytosine arabinoside in refractory or relapsed acute non-lymphocytic leukaemia: a report on 25 patients. Eur J Haematol1994;52:236239.

    • Search Google Scholar
    • Export Citation
  • 109

    Al-AliHKJaekelNJunghanssC. Azacitidine in patients with acute myeloid leukemia medically unfit for or resistant to chemotherapy: a multicenter phase I/II study. Leuk Lymphoma2012;53:110117.

    • Search Google Scholar
    • Export Citation
  • 110

    BlumWKlisovicRBHackansonB. Phase I study of decitabine alone or in combination with valproic acid in acute myeloid leukemia. J Clin Oncol2007;25:38843891.

    • Search Google Scholar
    • Export Citation
  • 111

    IssaJPGarcia-ManeroGGilesFJ. Phase 1 study of low-dose prolonged exposure schedules of the hypomethylating agent 5-aza-2'-deoxycytidine (decitabine) in hematopoietic malignancies. Blood2004;103:16351640.

    • Search Google Scholar
    • Export Citation
  • 112

    SmithGADamonLERugoHS. High-dose cytarabine dose modification reduces the incidence of neurotoxicity in patients with renal insufficiency. J Clin Oncol1997;15:833839.

    • Search Google Scholar
    • Export Citation
  • 113

    CornelyOAMaertensJWinstonDJ. Posaconazole vs. fluconazole or itraconazole prophylaxis in patients with neutropenia. N Engl J Med2007;356:348359.

    • Search Google Scholar
    • Export Citation
All Time Past Year Past 30 Days
Abstract Views 0 0 0
Full Text Views 821 821 59
PDF Downloads 192 192 20
EPUB Downloads 0 0 0